
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
New York-Eyetech Pharmaceuticals plans to extend an initial public offering of shares of its common stock.




